Key facts
- It has raised $29.5M; the latest was Later Stage VC in Jul 2025.
- Notable investors include Qianhai FoF, YuanBio Venture Capital, Guolian Investment, Wuxi Guolian Development (Group), Anyuan Fund — 11 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 11 names
- ·Watchlist + deal alerts for Shuwen Biotechnology
- ·The full record, as it builds
Funding rounds
No funding rounds for Shuwen Biotechnology are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Shuwen Biotechnology
Manufacturer of innovative in vitro diagnostic products focusing on women's health aims to lead global transformation in pregnancy and cancer screening. The company's offerings feature proprietary diagnostic assays for preeclampsia and breast cancer including the internationally pioneering Whanxian preeclampsia kit and prognostic test, accredited central laboratory services, certified IVD reagent production, and international collaborations, helping clinicians and pharmaceutical developers accelerate diagnosis, personalize treatment, and expand access to advanced womens health testing, enabling improved maternal and oncology outcomes worldwide.
- Sector
- Healthcare
- HQ
- Huzhou, China
- Founded
- 2010
- Website
- shuwendx.com/
- Ownership
- Privately Held (backing)
Shuwen Biotechnology doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Shuwen Biotechnology shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Shuwen Biotechnology in its N-PORT filings yet. We sweep new filings monthly.